A great new interview series with Prof. Scheibenbogen from Charité in Berlin
Part 1:
In this film we talk about the two types of Long Covid that were recognised in her paper that was published in Nature Communications, and just how big a role auto-immunity might play in driving the condition.
The paper discussed in the video: https://www.nature.com/articles/s41467-022-32507-6
Prof Scheibenbogen’s most recent scientific paper: https://www.frontiersin.org/articles/10.3389/fmicb.2023.1196721/full
Part 2:
In this film we ask Professor Scheibenbogen about her thoughts on viral persistence, and how you’d go about treating auto-immunity in the context of ME/CFS and Long Covid.
Linked papers therefore:
Long COVID: Association of Functional Autoantibodies against G-Protein-Coupled Receptors with an Impaired Retinal Microcirculation: https://www.mdpi.com/1422-0067/23/13/7209
Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection: https://www.frontiersin.org/articles/10.3389/fmed.2021.754667/full
Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854315/
Immunoadsorption to treat patients with severe post-COVID syndrome: https://pubmed.ncbi.nlm.nih.gov/36719401/
Part 3:
In this film we talk about how long it might be before we can expect to see effective treatments getting through phase 2 and phase 3 trials, and why it is that getting this research done takes so long.
Linked paper:
Fighting Post-COVID and ME/CFS – development of curative therapies: https://www.frontiersin.org/articles/10.3389/fmed.2023.1194754/full
